Needham & Company LLC Reaffirms Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Needham & Company LLC reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note issued to investors on Thursday, Benzinga reports. Needham & Company LLC currently has a $222.00 price target on the specialty pharmaceutical company’s stock.

A number of other brokerages have also recently commented on JAZZ. StockNews.com raised shares of Jazz Pharmaceuticals from a buy rating to a strong-buy rating in a report on Tuesday, January 30th. Stifel Nicolaus upped their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a buy rating in a report on Friday, March 15th. JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an overweight rating in a report on Friday, March 22nd. Barclays lowered their price target on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an overweight rating for the company in a report on Friday, March 1st. Finally, Robert W. Baird initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They issued an outperform rating and a $160.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $192.75.

Jazz Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ JAZZ traded up $0.72 during mid-day trading on Thursday, hitting $110.01. The stock had a trading volume of 693,769 shares, compared to its average volume of 597,957. The business has a 50 day moving average price of $116.44 and a two-hundred day moving average price of $121.10. The firm has a market cap of $6.94 billion, a P/E ratio of 22.68, a price-to-earnings-growth ratio of 1.51 and a beta of 0.63. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.85 and a current ratio of 2.27. Jazz Pharmaceuticals has a 1 year low of $103.01 and a 1 year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. On average, equities analysts anticipate that Jazz Pharmaceuticals will post 16.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Rise Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares during the period. Cape Investment Advisory Inc. boosted its holdings in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 292 shares in the last quarter. Covestor Ltd lifted its stake in Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after buying an additional 345 shares in the last quarter. Spire Wealth Management raised its position in Jazz Pharmaceuticals by 128.6% during the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 238 shares during the period. Finally, Headinvest LLC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $56,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.